Navigation Links
Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
Date:9/3/2009

CARY, N.C., Sept. 3 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at two upcoming investor conferences.

Mr. Collard will first present at the Thomas Weisel Partners Healthcare Conference 2009 at 4:25 PM ET on Wednesday, September 9th, 2009, at the Four Seasons Hotel in Boston, MA. He will then deliver the Company's corporate overview at the Rodman & Renshaw 11th Annual Healthcare Conference at 9:10 AM ET on Thursday, September 10th, 2009, at the New York Palace Hotel in New York City. Both conferences will be held from September 9th - 11th, 2009.

Live audio and archived webcasts of Cornerstone's presentations will be available through the Investor Relations section of the Company's website.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... MRI screening improves early diagnosis of breast cancer in ... online in the journal Radiology . , MRI has long been known ... ultrasound. Currently, guidelines reserve breast MRI screening for women who have a strong family ...
(Date:2/20/2017)... ... , ... Scrubbing in for his first esophageal cancer case in the late ... of the surgeon training him. , “He was giddy and almost couldn’t contain himself ... but I would do it for free,’” Dr. Pezzi recalled. “He genuinely was so ...
(Date:2/20/2017)... ... , ... The StayWell Company and VUCA Health announced ... risks, foster behavior change and improve health literacy among patients. VUCA Health, which created ... of its video capability at StayWell booth 3443 during HiMSS. , The VUCA ...
(Date:2/20/2017)... ... ... Population Health Software Company, is pleased to announce a move to a larger office building ... size of the previous location while bringing life back to a medical practice building that ... excited to expand our footprint to better serve our growing client base. We are ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, a ... during the 2017 Annual HIMSS Conference & Exhibition in Orlando, Florida, ... and integrating eye care into mainstream healthcare delivery is powered by Secure ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017  /PR Newswire/ -- UBM Medica,s ... announce the launch of Modern Retina ( ... retina specialists. Built upon the success of ... on the latest innovations in the areas of retinal ... management. By meeting current informational needs and filling existing ...
(Date:2/21/2017)... , Feb. 21, 2017   BeyondSpring ... on the development of innovative immuno-oncology cancer therapies, ... significant data from its Phase 2 trial of ... the treatment of non-small cell lung cancer (NSCLC) ... at this year,s ASCO-SITC Clinical Immuno-Oncology Symposium in ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
Breaking Medicine Technology: